MA29374B1 - Anticorps anti-ccr5 et leurs utilisations - Google Patents

Anticorps anti-ccr5 et leurs utilisations

Info

Publication number
MA29374B1
MA29374B1 MA30257A MA30257A MA29374B1 MA 29374 B1 MA29374 B1 MA 29374B1 MA 30257 A MA30257 A MA 30257A MA 30257 A MA30257 A MA 30257A MA 29374 B1 MA29374 B1 MA 29374B1
Authority
MA
Morocco
Prior art keywords
seq
constituted
cdr1
cdr2
group
Prior art date
Application number
MA30257A
Other languages
English (en)
Inventor
Michael Brandt
Suryanarayana Sankuratri
Ralf Schumacher
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29374B1 publication Critical patent/MA29374B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE UN ANTICORPS SE LIANT AU CCR5 HUMAIN, COMPRENANT UNE CHAÎNE LOURDE VARIABLE ET UNE CHAÎNE LÉGÈRE VARIABLE, SE CARACTÉRISANT EN CE QUE LA CHAÎNE LOURDE VARIABLE COMPREND DES SÉQUENCES CDR, CDR1, CDR2 ET CDR3, CDR1 ÉTANT SÉLECTIONNÉE DANS LE GROUPE CONSTITUÉ PAR SEQ ID NO: 9, 10, 11, 12, CDR2 ÉTANT SÉLECTIONNÉE DANS LE GROUPE CONSTITUÉ PAR SEQ ID NO: 13, 14, 15, CDR3 ÉTANT SÉLECTIONNÉE DANS LE GROUPE CONSTITUÉ PAR SEQ ID NO: 16, 17, LESDITES CDR ÉTANT SÉLECTIONNÉES INDÉPENDAMMENT LES UNES DES AUTRES, OU EST UN VARIANT HUMANISÉ CHIMÉRIQUE OU UN FRAGMENT DUDIT ANTICORPS. L'ANTICORPS SELON L'INVENTION PRÉSENTE DES PROPRIÉTÉS AVANTAGEUSES DANS LE TRAITEMENT DES MALADIES IMMUNOSUPPRESSIVES.
MA30257A 2005-04-01 2007-09-27 Anticorps anti-ccr5 et leurs utilisations MA29374B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007138 2005-04-01

Publications (1)

Publication Number Publication Date
MA29374B1 true MA29374B1 (fr) 2008-04-01

Family

ID=34934663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30257A MA29374B1 (fr) 2005-04-01 2007-09-27 Anticorps anti-ccr5 et leurs utilisations

Country Status (19)

Country Link
US (1) US7615216B2 (fr)
EP (2) EP1869087A2 (fr)
JP (2) JP4733736B2 (fr)
KR (1) KR20070116136A (fr)
CN (1) CN101175771A (fr)
AR (1) AR052959A1 (fr)
AU (1) AU2006228663A1 (fr)
BR (1) BRPI0609792A2 (fr)
CA (1) CA2603692A1 (fr)
CR (1) CR9393A (fr)
IL (1) IL186071A0 (fr)
MA (1) MA29374B1 (fr)
MX (1) MX2007011842A (fr)
NO (1) NO20074867L (fr)
RU (1) RU2007139953A (fr)
SG (1) SG151284A1 (fr)
TW (1) TW200720289A (fr)
WO (1) WO2006103100A2 (fr)
ZA (1) ZA200708332B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981911A2 (fr) * 2006-01-30 2008-10-22 F.Hoffmann-La Roche Ag Compositions synergiques destinees au traitement du vih
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
ATE550355T1 (de) * 2006-09-29 2012-04-15 Hoffmann La Roche Antikörper gegen ccr5 und ihre verwendung
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2011509958A (ja) * 2008-01-15 2011-03-31 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ５に対するアフコシル化抗体およびそれらの使用
WO2010028798A1 (fr) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Anticorps multivalents
WO2010028796A1 (fr) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Anticorps hexavalents trispécifiques
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
EP2435473B1 (fr) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Anticorps tri ou tétra-spécifiques
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
SG178973A1 (en) 2009-09-07 2012-04-27 Hoffmann La Roche Es-ms of glycopeptides for analysis of glycosylation
WO2011034605A2 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
CA2782571C (fr) 2009-12-22 2018-01-23 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012010582A1 (fr) 2010-07-21 2012-01-26 Roche Glycart Ag Anticorps anti-cxcr5 et leurs méthodes d'utilisation
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
KR102003075B1 (ko) * 2011-02-23 2019-07-23 에프. 호프만-라 로슈 아게 인간 il33r에 대한 항체 및 이의 용도
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
CA2824824A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Proteines monovalentes de liaison a l'antigene
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
BR112014006537A2 (pt) 2011-09-23 2017-11-28 Roche Glycart Ag anticorpos biespecíficos, formulação farmacêutica, usos de um anticorpo biespecífico, método de tratamento, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo biespecífico
ES2548215T3 (es) 2011-10-05 2015-10-14 F. Hoffmann-La Roche Ag Proceso para la producción de anticuerpos de la glicoforma G1
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
KR20150013188A (ko) 2012-05-24 2015-02-04 에프. 호프만-라 로슈 아게 다중특이적 항체
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015082446A1 (fr) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps anti-cdcp1 et d'un taxane
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
CA3046489A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procedes, dispositifs et systemes de detection du tractus gastro-intestinal
EP3554541B1 (fr) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du récepteur de chimiokine
US20210275589A1 (en) 2018-07-13 2021-09-09 Nanjing Legend Biotech Co. Ltd. Co-receptor systems for treating infectious diseases
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
JP7638989B2 (ja) * 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
EP0272253A4 (fr) 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US20030099645A1 (en) 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
US6610834B1 (en) 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
MXPA01006097A (es) 1998-12-16 2002-04-15 Progenics Pharm Inc Inhibicion sinergistica de la fusion y union de vih-1, composiciones y anticuerpos en la misma.
TR200102779T2 (tr) 1999-03-11 2002-03-21 Micromet Ag Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
CA2399593A1 (fr) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Recepteur hdgnr10 de la chimiokine de la proteine g humaine (ccr5)
US20040043033A1 (en) * 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US7005503B2 (en) * 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
EP1207202A1 (fr) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Molécules d'acide nucléique interagissant avec le récepteur de chémokines et d'autres membres de la famille de récepteurs de chémokines
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
AU2003209059A1 (en) 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
EP1478738B1 (fr) 2002-02-22 2008-11-12 Progenics Pharmaceuticals, Inc. Anticorps anti-ccr5
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody

Also Published As

Publication number Publication date
MX2007011842A (es) 2007-10-11
AR052959A1 (es) 2007-04-11
TW200720289A (en) 2007-06-01
CA2603692A1 (fr) 2006-10-05
US20070036796A1 (en) 2007-02-15
SG151284A1 (en) 2009-04-30
CR9393A (es) 2008-02-20
ZA200708332B (en) 2009-04-29
JP2011079836A (ja) 2011-04-21
RU2007139953A (ru) 2009-05-10
EP2336183A3 (fr) 2011-10-12
KR20070116136A (ko) 2007-12-06
WO2006103100A3 (fr) 2006-12-28
EP2336183A2 (fr) 2011-06-22
US7615216B2 (en) 2009-11-10
JP2008533998A (ja) 2008-08-28
JP4733736B2 (ja) 2011-07-27
CN101175771A (zh) 2008-05-07
NO20074867L (no) 2007-12-07
WO2006103100A2 (fr) 2006-10-05
BRPI0609792A2 (pt) 2010-04-27
AU2006228663A1 (en) 2006-10-05
EP1869087A2 (fr) 2007-12-26
IL186071A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
RU2505603C2 (ru) Антитело против рецептора il-6
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
NZ599683A (en) Anti-ilt7 antibody
TNSN04078A1 (fr) Antibodies to cd40
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2005110474A3 (fr) ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
MA33387B1 (fr) Polypeptides et procede de traitement
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
HRP20090527T1 (hr) Imunoglobulini za neutraliziranje nogo-a, namijenjeni liječenju neuroloških bolesti
EP2046836A4 (fr) Anticorps se liant spécifiquement à dr5 et composition destinée à prévenir ou traiter des cancers et comprenant cet anticorps
NZ597611A (en) Anti notch-1 antibodies
MA38161A1 (fr) Anticorps anti-bmp-6